Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00817271 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Response to Glucagon During Hypoglycemia
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00817271 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 8 participants.
The verdict
NCT00817271, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the response to Glucagon versus the spontaneous hormonal response to low blood sugar levels in T2DM Patients treated with AZD1656 and Metformin
Interventions
- DRUG Glucagon
- DRUG AZD1656
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00817271
The ClinicalTrials.gov registry entry for NCT00817271 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glucagon is the first listed.
NCT00817271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00817271 about?
NCT00817271 is a clinical study titled "To Evaluate the Response to Glucagon During Hypoglycemia". The purpose of this study is to evaluate the response to Glucagon versus the spontaneous hormonal response to low blood sugar levels in T2DM Patients treated with AZD1656 and Metformin
What is the current status of trial NCT00817271?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2009-02. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00817271?
The interventions under investigation include: Glucagon (DRUG), AZD1656 (DRUG).
Who is sponsoring clinical trial NCT00817271?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.